-

Mainstay Medical to Present at the LifeSci Partners Summer Symposium

DUBLIN--(BUSINESS WIRE)--Mainstay Medical Holdings plc (“Mainstay” or the “Company”) today announced that Jason Hannon, Chief Executive Officer, and Matthew Onaitis, Chief Financial Officer, will present a corporate overview at the LifeSci Partners Private Healthcare Company Virtual Summer Symposium on Wednesday, 5 August, 2020.

Presentation Details:

Date:

5 August, 2020

Time:

2:30 PM ET

To register, please click here.

About Mainstay Medical Holdings
Mainstay Medical Holdings is a medical device company focused on commercializing an innovative implantable restorative neurostimulation system, ReActiv8®, for people with disabling Chronic Low Back Pain (CLBP). The Company is headquartered in Dublin, Ireland and has subsidiaries operating in Ireland, the United States, Australia, Germany and the Netherlands.

Contacts

PR and IR Enquiries:

LifeSci Advisors, LLC (IR for U.S.)
Brian Ritchie
Tel: + 1 (212) 915-2578
Email: britchie@lifesciadvisors.com

The Ruth Group (PR for U.S.)
Annika Haberland
Tel: +1 (720) 412-9042
Email: ahaberland@theruthgroup.com

FTI Consulting (for Ireland/Europe)
Jonathan Neilan or Patrick Berkery
Tel. : +353 1 765 0886
Email: mainstay@fticonsulting.com

Industry:

Mainstay Medical Holdings plc

Release Versions
English

Contacts

PR and IR Enquiries:

LifeSci Advisors, LLC (IR for U.S.)
Brian Ritchie
Tel: + 1 (212) 915-2578
Email: britchie@lifesciadvisors.com

The Ruth Group (PR for U.S.)
Annika Haberland
Tel: +1 (720) 412-9042
Email: ahaberland@theruthgroup.com

FTI Consulting (for Ireland/Europe)
Jonathan Neilan or Patrick Berkery
Tel. : +353 1 765 0886
Email: mainstay@fticonsulting.com

More News From Mainstay Medical Holdings plc

Mainstay Medical Announces U.S. FDA Approval of ReActiv8® Neurostimulation System for Chronic Low Back Pain

DUBLIN--(BUSINESS WIRE)--Mainstay Medical Holdings plc (“Mainstay” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s Premarket Approval (PMA) application for ReActiv8®, its implantable neurostimulation system to treat intractable chronic low back pain. Jason Hannon, CEO of Mainstay, said: “I am so proud of our team and the dedicated physicians who managed our clinical trials and cared for their patients. We are thrilled to receive FDA...

Mainstay Medical Announces Reimbursement Approval for ReActiv8 in Australia

DUBLIN--(BUSINESS WIRE)--Mainstay Medical Holdings plc (“Mainstay” or the “Company”), today announced that ReActiv8, its implantable restorative neurostimulation system to treat disabling Chronic Low Back Pain, has been approved for inclusion in the Prostheses List of reimbursed products in Australia, effective as of 1 July 2020. The Prostheses List identifies implantable devices eligible for reimbursement from all private health insurance funds in Australia. This approval follows the December...

Mainstay Medical UK Regulatory Announcement: Total Voting Rights

DUBLIN--(BUSINESS WIRE)--  Mainstay Medical International plc (“Mainstay” or the “Company”) Total Voting Rights In conformity with Regulation 20 of the Transparency (Directive 2004/109/EC) Regulations 2007, Mainstay announces that: The total number of Ordinary Shares of nominal value €0.001 each in issue on 3 June 2020 is 13,439,004 corresponding to a total of 13,439,004 voting rights. The Company holds no Ordinary Shares in treasury. Therefore, the figure which may be used by shareholders as t...
Back to Newsroom